TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1357070
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, every 6 hours for 48 hours) + Placebo + GHRH (100 micrograms i.v.)
Study: 3899675
Drug: Citalopram 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 25 mg once daily
Study: 3899675
Drug: Citalopram 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 50 mg once daily
Study: 3899675
Drug: Citalopram (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (various doses)
Study: 28296349
Drug: α-glucosidase inhibitors
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-glucosidase inhibitors (αGI)
Study: 18458306
Drug: Primaquine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine, 30 mg a day for 5 days
Study: 18458306
Drug: Primaquine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine, 30 mg a day for 7 days
Study: 18458306
Drug: Primaquine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine, 30 mg a day for 9 days
Study: 18458306
Drug: Primaquine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine, 30 mg a day for 11 days
Study: 18458306
Drug: Primaquine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine, 30 mg a day for 14 days
Study: 18458306
Drug: Primaquine, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine, 30 mg twice a day for 7 days
Study: 11253883
Drug: Intracameral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral pilocarpine (0.13 mg/ml in BSS)
Study: 31168046
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for STEMI
Study: 31168046
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for AP
Study: 22669229
Drug: Multimodal hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal hand hygiene improvement strategy (training sessions, hydroalcoholic solutions, reminder posters)
Study: 15954910
Drug: Long-acting somatostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting somatostatin (octreotide-LAR, 40 mg intramuscularly every 28 days)
Study: 12410487
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) at a dose of 0.1 mg/kg/day
Study: 11030804
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (50 mg)
Study: 11030804
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene supplementation (20 mg)
Study: 8835043
Drug: Amoxicillin (Trimox)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (Trimox)
Study: 8835043
Drug: Amoxicillin (Amoxil)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (Amoxil)
Study: 31953303
Drug: Tacrolimus (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.05 mg/kg twice daily)
Study: 31953303
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg daily up to 60 mg daily)
Study: 28931411
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg per day as add-on therapy to antipsychotics)
Study: 28931411
Drug: Placebo (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (treatment as usual with antipsychotics)
Study: 26167680
Drug: Individualized-protocol with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized-protocol with adjusted injection rate based on patient weight and contrast medium concentration (280 mgI/kg)
Study: 26167680
Drug: Conventional contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional contrast injection protocol with total injection volume of 80ml and constant injection rate of 5.5ml/s
Study: 21519151
Drug: Control (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ACE inhibitor treatment without β-blockade)
Study: 10714475
Drug: 10-day moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day moxifloxacin 400 mg once daily
Study: 8299614
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (400 mg)
Study: 2153424
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg)
Study: 18801303
Drug: Rocuronium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.15 mg/kg repeated doses
Study: 9366716
Drug: Parenteral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral group (n = 86)
Study: 2737225
Drug: Alifedrine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alifedrine 50 mg
Study: 17445351
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of 1440 kJ serving of almonds for 10 weeks
Study: 17445351
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of almonds
Study: 7672677
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily plus amoxicillin 1 g twice daily
Study: 7672677
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice daily plus amoxicillin 1 g twice daily
Study: 17037995
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs); duration 8-16 weeks.
Study: 12632615
Drug: Colloid preloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preloading (6% hydroxyethyl starch; HES) at 8 ml.kg‐1 before spinal anesthesia
Study: 11013810
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis (PAP) as per the quality standard developed in 1994.
Study: 1678643
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of oral calcium supplementation/day for three months postoperatively
Study: 25294589
Drug: Enoxaparin 2000
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 2000 IU subcutaneously twice daily
Study: 20353031
Drug: Zishen Shengxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zishen Shengxue Recipe (ZSR) combined with subcutaneous injection of erythropoiesis stimulating factor (rHuEpo)
Study: 12153828
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (tricyclic antidepressants and phenelzine)
Study: 12153828
Drug: Psychotherapy (primarily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (primarily cognitive behavior and interpersonal therapies)
Study: 8537416
Drug: No pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pressure garment therapy
Study: 2197046
Drug: TP‐1 (Serono;
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP‐1 (Serono; 1 mg/kg body weight) administered by daily i.m. injections for the first 14 days followed by two injections/week for 6 further weeks
Study: 6363099
Drug: Regular +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular + NPH‐Biosynthetic human insulin
Study: 20939917
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (8 sessions)
Study: 7038945
Drug: 4.5 milligram
Normalized name: Product containing precisely ganciclovir 4.5 milligram/1 each prolonged-release ocular implant (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 milligram epidurally administered morphine sulfate
Study: 7038945
Drug: 2 milligram
Normalized name: Clonazepam 2 MILLIGRAM In 1 TABLET ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 milligram epidurally injected morphine sulfate
Study: 17445637
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (10 g)
Study: 17445637
Drug: DMSO with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMSO with lidocaine (10 g of 40% DMSO)
Study: 15127090
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg twice daily)
Study: 2769581
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) mean daily intake of 1.29 grams
Study: 2769581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 healthy persons similar in age, taking no medication)
Study: 30101
Drug: Naloxone (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4.0 mg intravenous injection)
Study: 2417477
Drug: Theophylline (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (oral, 8 to 22 micrograms/ml serum concentration)
Study: 22873530
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tofacitinib twice daily
Study: 22873530
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tofacitinib twice daily
Study: 22873531
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg adalimumab once every 2 weeks
Study: 18583219
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (1 microg/mL naloxone and 1 mg/mL morphine)
Study: 18583219
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (0 microg/mL naloxone and 1 mg/mL morphine)
Study: 9077048
Drug: Hypnotic techniques
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic techniques (audiotape with relaxation induction and posthypnotic suggestions)
Study: 9077048
Drug: No hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hypnotic techniques (control group)
Study: 22143258
Drug: Progestin-only contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-only contraceptive pills
Study: 22143258
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal contraceptive pills
Study: 22143258
Drug: Progestin-only and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-only and Combined hormonal contraceptive pills
Study: 20464321
Drug: Subgroup A
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup A - F applied to enamel without an intermediate bonding agent layer
Study: 18433918
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment after 6 weeks of pegylated interferon‐alpha2a/ribavirin therapy
Study: 18433918
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment after 6 weeks of pegylated interferon‐alpha2a/ribavirin therapy
Study: 15755826
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling (and placebo capsules)
Study: 15755826
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no dietary counseling and placebo capsules)
Study: 14650955
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) plus leucovorin (LV) therapy for 6 months after curative resection of Dukes' C CRC
Study: 14650955
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination of UFT and LV
Study: 14650955
Drug: Intrahepatic arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrahepatic arterial infusion (IHA) therapy
Study: 14650955
Drug: CPT‐11 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 as second-line therapy
Study: 2005224
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tetracycline-containing fibers and scaling
Study: 6856646
Drug: Cocaine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (16 mg, 32 mg, 48 mg)
Study: 28301859
Drug: Social learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social learning and cognitive behavioral therapy in-person (SLCBT)
Study: 28301859
Drug: Social learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social learning and cognitive behavioral therapy (remote condition only)
Study: 23033237
Drug: Closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop therapy
Study: 27532830
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (sensor-augmented pump therapy)
Study: 27532830
Drug: Closed-loop therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop therapy and Control therapy
Study: 21979301
Drug: Prulifloxacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin (600 mg daily for 14 days) + FERTIMEV (1 vial daily for 6 months)
Study: 8239223
Drug: Zileuton 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 2.4 g/d
Study: 8239223
Drug: Zileuton 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 1.6 g/d
Study: 25108907
Drug: HTO with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTO with platelet-rich plasma (PRP) injection only (n = 23)
Study: 25108907
Drug: HTO with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTO with MSC therapy and PRP injection (n = 21)
Study: 23441529
Drug: Methoxy polyethylene
Normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxy polyethylene glycol-epoetin beta (CERA) at alternative dose (113.08 mcg/month)
Study: 12150309
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin
Study: 19202954
Drug: Enoxaparin once
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin once daily
Study: 15926135
Drug: Pregabalin at
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin at doses of 150 mg to 600 mg per day
Study: 9861552
Drug: Methylphenidate (5.0-30.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5.0-30.0 mg)
Study: 9861552
Drug: d-Amphetamine (2.5-20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (2.5-20.0 mg)
Study: 27463
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mepindolol
Study: 27463
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg pindolol
Study: 29284465
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (3 times per week)
Study: 29284465
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride (5 mg/day for first 4 weeks, then 10 mg/day thereafter)
Study: 25544195
Drug: Hypericum 900-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum 900-1500 mg/day
Study: 7963447
Drug: Sertraline 50-100
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-100 mg/day
Study: 21307717
Drug: Dexamethasone 0.15
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.15 mg/kg every 6 hours for 4 days
Study: 11728676
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (Viagra) 50 mg for 2 weeks, increased to 100 mg if needed; duration of treatment was 12 weeks.
Study: 3497379
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered amoxicillin
Study: 29216937
Drug: PPI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI group (PPI < 1.4 for diagnosis, PPI > 2 for treatment)
Study: 25363415
Drug: Tarafenacin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarafenacin 0.4 mg
Study: 25363415
Drug: Tarafenacin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarafenacin 0.2 mg
Study: 17845648
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (40 ml)
Study: 17845648
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine (40 ml)
Study: 7912539
Drug: BRL35135 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL35135 8 mg
Study: 2645808
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg midazolam with 0.015-0.02 mg/kg atropine (Group I)
Study: 2645808
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg midazolam with 0.015-0.02 mg/kg atropine (Group II)
Study: 329858
Drug: Bromocriptine (2-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2-5 mg twice daily)
Study: 30548573
Drug: Gamma-hydroxybutyric acid
Normalized name: gamma-Hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-hydroxybutyric acid (GHB) administration
Study: 21521895
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL deionized water
Study: 18444872
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG 7909 adjuvant plus HBV vaccine
Study: 18444872
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (HBV vaccine without CPG 7909)
Study: 12574791
Drug: Liquorice consumption
Normalized name: Liquorice
DrugBank: Licorice (DB10675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquorice consumption (100 g daily for 4 weeks, 150 mg glycyrrhetinic acid)
Study: 10959541
Drug: d-amphetamine (AMP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (AMP; 10 and 20 mg)
Study: 10959541
Drug: ethanol (EtOH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethanol (EtOH; 0.2, 0.4, and 0.8 g/kg)
Study: 9379784
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral buspirone
Study: 9379784
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral buspirone
Study: 26478208
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg/day + single-dose i.v. ketamine (0.5 mg/kg over 40 min)
Study: 26478208
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg/day + placebo (0.9% i.v. saline)
Study: 19186971
Drug: Non-submerged implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-submerged implants
Study: 19186971
Drug: Submerged implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged implants
Study: 17593904
Drug: Fructose beverage
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose beverage (50 g)
Study: 17593904
Drug: Glucose beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose beverage (50 g)
Study: 17593904
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein beverage (50 g)
Study: 14999213
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (6 sessions of abdominal breath training, heart and respiratory physiologic feedback, daily breathing practice)
Study: 9459398
Drug: oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral cefixime
Study: 9459398
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum IL‐6 values >400 pg/ml
Study: 23743804
Drug: STITCH2-care (simplified
Approvals — FDA: no, EMA: no, PMDA: no
Description: STITCH2-care (simplified treatment algorithm featuring single-pill combinations)
Study: 9356764
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/day plus 4 g/day glucose)
Study: 9356764
Drug: Placebo (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (24 g/day glucose)
Study: 3882125
Drug: Isotretinoin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (40 mg daily for 2 months)
Study: 3882125
Drug: Etretinate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (50 mg daily for 2 months)
Study: 20357588
Drug: French physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: French physical therapy (PT)
Study: 12454831
Drug: PAC7 (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC7 (pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, all twice daily for 7 days)
Study: 12454831
Drug: PBTM7 (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBTM7 (pantoprazole 40 mg twice daily, bismuth subcitrate 108 mg, tetracycline 500 mg, both 4 times daily, metronidazole 200 mg 3 times daily and 400 mg at night for 7 days)
Study: 12454831
Drug: BTM14 (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTM14 (bismuth subcitrate 108 mg and tetracycline 500 mg, both 4 times daily, metronidazole 200 mg 3 times daily and 400 mg at night for 14 days)
Study: 10037123
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma from whole-blood preparation, adjusted to 10 x 10(9) platelets per mL
Study: 10037123
Drug: Platelets collected
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelets collected by apheresis, adjusted to 20 x 10(9) platelets per mL